Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 173

Sort by

Sort Order Select

Journal Articles

A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone

James R Berenson, Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi M. Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Matthew Brobeck, Regina Swift, Benjamin M. Eades, Sean Bujarski, Yohana Sebhat, Rudra Ray, Susanna Kim, Robert Allen Vescio

Blood (2023) 142 (Supplement 1): 4753.

https://doi.org/10.1182/blood-2023-180287

Published: 2023

Journal Articles

Outcomes of Triple Class Refractory Multiple Myeloma Patients: A Single Center Retrospective Study

Ryan Danis, David Yashar, Sean Bujarski, Scott Jew, Regina Swift, James R Berenson

Blood (2023) 142 (Supplement 1): 3369.

https://doi.org/10.1182/blood-2023-187318

Published: 2023

Journal Articles

Medical Writing Bias in Myeloma Clinical Research: A Comprehensive Analysis

Adam ElSayed, Sarah Mettias, Susanna Kim, Ryan Danis, James R Berenson

Blood (2023) 142 (Supplement 1): 5092.

https://doi.org/10.1182/blood-2023-186824

Published: 2023

Journal Articles

Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, Daisy Martinez, Tahmineh Safaie, Ralph Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Gary Edward Schwartz, Shahrooz Eshaghian, Regina Swift, Benjamin Eades, Sean Elliott Bujarski, Bernard Sean Regidor, Clara Kim, Susanna Kim, Robert Vescio

Blood (2022) 140 (Supplement 1): 12610–12611.

https://doi.org/10.1182/blood-2022-163872

Published: 2022

Journal Articles

Repotrectinib Alone and in Combination with Immunomodulatory Drugs Exhibits Potent Anti-Multiple Myeloma Activity

Haiming Chen, Eric Souther, Mingjie Li, Marissa-Skye Goldwater, Stacy Behare, Ava Hekmati, Huixin Yu, Isabella Nassir, Ariella Nassir, Ning Xu, James R. Berenson

Blood (2022) 140 (Supplement 1): 12460–12461.

https://doi.org/10.1182/blood-2022-167862

Published: 2022

Journal Articles

Ruxolitinib Enhances Anti-MM Function of Cytotoxic T-Cells By Upregulating IFNγ and Gzmb

Haiming Chen, Mingjie Li, Marissa-Skye Goldwater, Stacy Behare, Ava Hekmati, Huixin Yu, Isabella Nassir, Ariella Nassir, Charles David Deighton, Ning Xu, James R. Berenson

Blood (2022) 140 (Supplement 1): 12459.

https://doi.org/10.1182/blood-2022-167768

Published: 2022

Journal Articles

The JAK Inhibitor Pacritinib Suppresses the Checkpoint Proteins Pvrig and Tigit Expression on T Cells in Multiple Myeloma Patients

Ning Xu, Mingjie Li, Marissa-Skye Goldwater, Stacy Behare, Ava Hekmati, Huixin Yu, Isabella Nassir, Ariella Nassir, Charles David Deighton, Haiming Chen, James R. Berenson

Blood (2022) 140 (Supplement 1): 12458.

https://doi.org/10.1182/blood-2022-167320

Published: 2022

Journal Articles

Evaluation of Repotrectinib's Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone in Vitro and Ex Vivo

Haiming Chen, Eric Souther, Mingjie Li, Marissa-Skye Goldwater, Stacy Behare, Ava Hekmati, Huixin Yu, Isabella Nassir, Ariella Nassir, Ning Xu, James R. Berenson

Blood (2022) 140 (Supplement 1): 4213–4214.

https://doi.org/10.1182/blood-2022-169890

Published: 2022

Journal Articles

Dominant Expression of PVRIG and TIGIT Inhibitory Pathways in Bone Marrow of Multiple Myeloma Patients

Masha Frenkel, Zoya Alteber, Ning Xu, Mingjie Li, Haiming Chen, Gady Cojocaru, James R. Berenson, Eran Ophir

Blood (2021) 138 (Supplement 1): 4717.

https://doi.org/10.1182/blood-2021-148052

Published: 2021

Journal Articles

Anti-Myeloma Effects of Panobinostat in Combination with Duvelisib

Haiming Chen, Mingjie Li, Marissa Goldwater, Stacy Behare, Jasmin Cao, Cara Wallingford, Ava Hekmati, Rocky Levin, Eric Souther, Ning Xu, James R. Berenson

Blood (2021) 138 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2021-153983

Published: 2021

Journal Articles

Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients

Samuel D. Stampfer, Marissa-Skye Goldwater, Bernard Sean S. Regidor, Scott Kristian Jew, Sean Elliott Bujarski, Haiming Chen, David Yashar, Ning Xu, Mingjie Li, Tracy Green, Eddie Fung, Elias Aquino, Regina Swift, Shahrooz Eshaghian, Aaron Feinstein, James R. Berenson

Blood (2021) 138 (Supplement 1): 2712.

https://doi.org/10.1182/blood-2021-154287

Published: 2021

Journal Articles

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma

James R. Berenson, Daisy Martinez, Tahmineh Safaie, Noemi Silagan, Jennifer To, Tanya M. Spektor, Eli Forouzan, Regina Swift, Benjamin Eades, Shahrooz Eshaghian, Gary Schwartz, Ralph V. Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Robert Vescio

Blood (2021) 138 (Supplement 1): 2727.

https://doi.org/10.1182/blood-2021-151016

Published: 2021

Journal Articles

Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab

David Yashar, Bernard Sean S. Regidor, Scott Kristian Jew, Sean Bujarski, Marissa-Skye Goldwater, Regina Swift, Gary Edward Schwartz, Shahrooz Eshaghian, Robert Vescio, James R. Berenson

Blood (2021) 138 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2021-154350

Published: 2021

Journal Articles

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

James R. Berenson, MD, Noemi Silagan, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, Eli Forouzan, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Ralph V. Boccia, MD, Honghao Hank Yang, Stephen Lim, MD, Robert Vescio, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-143005

Published: 2020

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Sean Bujarski, BA, Kyle Udd, BA, Camilia Soof, BS, Tanya M. Spektor, PhD, Tahmineh Safaie, Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Joshua Stern, Cathy S. Wang, BS, Ning Xu, PhD, Marsiye Emamy-Sadr, Regina Swift, Ashkon Rahbari, Saurabh Patil, BS, Eric Souther, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1786.

https://doi.org/10.1182/blood-2019-132012

Published: 2019

Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD

Blood (2019) 134 (Supplement_1): 1853.

https://doi.org/10.1182/blood-2019-128760

Published: 2019

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Ning Xu, PhD, Nicole Ng, BS, Mingjie Li, BS, Erin Yu, BS, Eric Sanchez, BA, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Haiming Chen, MD PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 1824.

https://doi.org/10.1182/blood-2019-131047

Published: 2019

Journal Articles

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Janna Yu, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4402.

https://doi.org/10.1182/blood-2019-130888

Published: 2019

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Haiming Chen, MD PhD, Mingjie Li, BS, Eric Sanchez, BA, Nicole Ng, BS, Erin Yu, BS, Sean Bujarski, BA, Zhengyi Yin, Tara Hekmati, Dylan Field, Jasper Wang, Isabella Nassir, Justin Huang, David Daniely, Cathy S. Wang, BS, Ning Xu, PhD, James R. Berenson, MD

Blood (2019) 134 (Supplement_1): 4352.

https://doi.org/10.1182/blood-2019-131324

Published: 2019

NARROW

A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone

Outcomes of Triple Class Refractory Multiple Myeloma Patients: A Single Center Retrospective Study

Medical Writing Bias in Myeloma Clinical Research: A Comprehensive Analysis

Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Repotrectinib Alone and in Combination with Immunomodulatory Drugs Exhibits Potent Anti-Multiple Myeloma Activity

Ruxolitinib Enhances Anti-MM Function of Cytotoxic T-Cells By Upregulating IFNγ and Gzmb

The JAK Inhibitor Pacritinib Suppresses the Checkpoint Proteins Pvrig and Tigit Expression on T Cells in Multiple Myeloma Patients

Evaluation of Repotrectinib's Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone in Vitro and Ex Vivo

Dominant Expression of PVRIG and TIGIT Inhibitory Pathways in Bone Marrow of Multiple Myeloma Patients

Anti-Myeloma Effects of Panobinostat in Combination with Duvelisib

Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma

Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma

The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only